15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform Download PDF Post navigationPreviousPrevious post:AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)NextNext post:AB Science webcast – Microtubule Destabilizer Agents (MDA) platformRelated PostsRevenues for the first half of 2023 and update on AB Science’s activitiesSeptember 29, 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037June 1, 2023AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023May 30, 2023AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037June 1, 2023
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023
